Abstract
The antibody response to respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a major focus of COVID-19 research due to its clinical relevance and importance in vaccine and therapeutic development. Neutralizing antibody (NAb) evaluations are useful for the determination of individual or herd immunity against SARS-CoV-2, vaccine efficacy, and humoral protective response longevity, as well as supporting donor selection criteria for convalescent plasma therapy. In the current manuscript, we review the essential concepts of NAbs, examining their concept, mechanisms of action, production, and the techniques used for their detection; as well as presenting an overview of the clinical use of antibodies in COVID-19.
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference175 articles.
1. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
2. Coronavirus COVID-19 Dashboard by the Center for Systems Science and Engineering (Csse). Johns Hopkins University-Baltimorehttps://coronavirus.jhu.edu/map.html
3. Who Coronavirus Disease (COVID-19) Dashboardhttps://covid19.who.int
4. (A Little) Clarity on Convalescent Plasma for Covid-19
5. Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献